health
GSK reports promising early results in ovarian and womb cancer drug trial
Mo-Rez reduced or eliminated tumours in over 60% of patients and is expected to be a blockbuster drug
TL;DR
- Mo-Rez shrank or eliminated tumors in 62% of ovarian cancer patients and 67% of endometrial cancer patients in early trials.
- The treatment showed a promising clinical profile, with few patients stopping due to side-effects like nausea.
- GSK plans to proceed directly to late-stage trials based on these positive results.
- Mo-Rez is expected to be a blockbuster drug with peak annual sales exceeding £2 billion.
- CEO Luke Miels is focused on speeding up drug development and demonstrating 'scientific courage'.